HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) Files An 8-K Submission of Matters to a Vote of Security Holders

HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

Story continues below

On May 2, 2018, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. Of the 143,731,420 shares of the Company's common stock outstanding as of the record date, 121,150,832 shares were represented at the annual meeting.

The stockholders considered four proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 22, 2018. The number of votes cast for and against (or withheld) and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below.

Proposal 1: Election of two Class II directors to hold office for a three-year term expiring at the 2021 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:

Names

Votes For

Withheld

Broker Non-Votes

Jean-Pierre Bizzari, M.D.

89,579,812

4,881,409

26,689,611

James M. Daly

93,234,853

1,226,368

26,689,611

Each of the foregoing candidates were elected and each received affirmative votes from more than a majority of the outstanding shares.

Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:

Votes For

Votes Against

Abstain

Broker Non-Votes

88,282,694

5,994,854

183,673

26,689,611

The foregoing proposal was approved.

Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018 was as follows:

Votes For

Votes Against

Abstain

Broker Non-Votes

120,501,435

534,454

114,943

The foregoing proposal was approved.

Proposal 4: The vote on a proposal to approve amendments to the Amended and Restated 2011 Stock Plan was as follows:

Votes For

Votes Against

Abstain

Broker Non-Votes

89,114,872

5,106,414

239,935

26,689,611

The foregoing proposal was approved.


About HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

An ad to help with our costs